# IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC

Source: https://onco.cc/trials/nct05994131/  
OnCo record `nct05994131` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of IN10018 and Furmonertinib in non-small-cell lung cancer, run by InxMed (Shanghai) Co., Ltd., now recruiting.

## Summary

IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC is a phase 1/2 interventional study registered as NCT05994131 by InxMed (Shanghai) Co., Ltd., with 110 participants planned, started 2023-07-13 and due to reach its primary completion in 2026-07-31. Interventions recorded: IN10018 and Furmonertinib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05994131
- Phase: 1/2
- Setting: A Multicenter, Open-label, Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerance, Pharmacokinetics and Anti-tumor Efficacy of IN10018 Combined With Third-generation EGFR-TKI in Patients With Advanced EGFR Mutation-positive NSCLC
- Sponsor: InxMed (Shanghai) Co., Ltd.
- Enrolled: 110

## Sources

- ClinicalTrials.gov NCT05994131: https://clinicaltrials.gov/study/NCT05994131

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Furmonertinib](https://onco.cc/drugs/furmonertinib/), [IN10018](https://onco.cc/drugs/in10018/)

---
JSON: https://onco.cc/api/v1/entities/nct05994131.json